

Data Sheet

NAME :	vTF <i>nef</i>
REPOSITORY REFERENCE :	ARP2111
PROVIDED:	1 vial cell-free virus at 1.2×10^8 pfu/ml
HOST:	Confluent monkey kidney cell lines (CV-1, Vero)
CLONING SITE:	Vaccinia virus thymidine kinase gene
STERILITY:	Negative for bacteria and mycoplasma
DESCRIPTION:	The HIV-1 <i>nef</i> ORF was isolated from the plasmid pNLXho, a pNL432 derivative. A <i>Bam</i> HI fragment was blunt end ligated to pSCII (from Dr. Bernard Moss) and cleaved with <i>Sma</i> I to produce the plasmid pTF <i>nef</i> . This clone contains the <i>nef</i> coding sequence under transcriptional control of the vaccinia P7.5 promoter. The transcriptional cassette was inserted into the vaccinia virus TK gene by homologous recombination to produce vTF <i>nef</i> .
SPECIAL CHARACTERISTICS :	Infect host cells with 2 – 5 pfu/ml of vaccinia. Harvest cells after 30-40 hours when extensive CPE are evident. Sonicate or freeze-thaw the cells three times and clarify by centrifugation. The control vaccinia virus is vSC8.
STORAGE :	Liquid Nitrogen

SOURCE :

MedImmune, Incorporated (courtesy of NIH AIDS Research and Reference Reagent Programme.)

REFERENCE :

Koenig S, Fuerst TR, Wood LV, Woods RM, Suzich JA, Jones GM, de la Cruz VF, Davey RT Jr, Venkatesan S, Moss B, Biddison WE, Fauci AS. Mapping the fine specificity of a cytolytic T cell response to HIV – 1 nef protein. *J Immunol* **145**:127-135, 1990

ACKNOWLEDGEMENTS :

Publications should acknowledge the donor of the reagent and the Programme EVA Centre for AIDS Reagents. Suggested wording can be found on our website at <http://www.nibsc.ac.uk/spotlight/aidsreagent/index.html> in the “Acknowledgements” section.

Please also ensure that you send us a copy of any papers resulting from work using reagents acquired through CFAR (this can be electronically or as a paper copy)

The US Government has submitted a patent application on the parent plasmid pSC11. Scientists at for-profit institutions or who intend commercial use of this reagent must contact Cindy Fuchs, NIAID Office of Technology Development, Tel: 301-496-2644, before the reagent can be released, and also to Dr. Michael Richman, MedImmune Inc., .35 West Watkins Mill Road, Gaithersburg, MD 20878, Tel: 301-417-0770.